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INTRODUCTION
While symptomatic patients with occupational asthma (OA) 
have non-specific airway hyper-responsiveness (NSAH), their 
NSAH may disappear after exposure to the offending agent ceas-
es. Conversely, the induction of an asthmatic reaction after spe-
cific bronchial provocation testing is often associated with an 
increase in NSAH.
1,2 This report is about a dental implant work-
er with symptoms of OA. His job involved blasting titanium for 
dental implants with hydroxyapatite. A specific bronchial prov-
ocation test with hydroxyapatite showed an early asthmatic re-
sponse. However, no NSAH to methacholine was seen before 
or after the hydroxyapatite provocation test. To our knowledge, 
this is the first report of hydroxyapatite-induced OA, and it was 
not accompanied by increased NSAH after a specific bronchial 
provocation test.
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CASE REPORT
The patient was a 38-year-old male, non-smoker, who had 
been employed in a dental implant factory for 1.5 years. His work 
consisted of treating titanium surfaces with hydroxyapatite in a 
blasting machine. One year after starting his job, the patient de-
veloped rhinorrhea, a paroxysmal cough, and chest tightness. 
His symptoms were aggravated during and shortly after work 
and subsided several hours after work. When the patient stopped 
working for 2 months because of chest symptoms, he became 
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Hydroxyapatite is commonly used as a filler to replace amputated bone or as a coating to promote bone ingrowth into prosthetic implants. Many mod-
ern implants, such as hip replacements and dental implants, are coated with hydroxyapatite. We report a patient with occupational asthma due to 
hydroxyapatite, proven by a specific inhalation challenge, who experienced an early asthmatic reaction after exposure to hydroxyapatite, without in-
creased airway responsiveness to methacholine despite an increased eosinophil count in the peripheral blood. A 38-year-old male dental implant 
worker visited our allergy department for the evaluation of occupational asthma. He had treated dental implant titanium surfaces with hydroxyapa-
tite for 1.5 years. One year after starting his employment, he noticed symptoms of rhinorrhea, paroxysmal cough, and chest tightness. His symptoms 
were aggravated during and shortly after work and subsided several hours after work. When he stopped working for 2 months because of his chest 
symptoms, he became asymptomatic. After restarting his work, his symptoms reappeared and were aggravated. A methacholine bronchial challenge 
test had a negative response. The following day, a specific bronchial provocation test with wheat powder was negative. On the third day, a specific 
bronchial provocation test with hydroxyapatite powder produced an early asthmatic response. On the fourth day, a methacholine bronchial challenge 
test was negative. Further studies are needed to evaluate the exact pathogenetic mechanism of hydroxyapatite-induced occupational asthma.
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asymptomatic. After restarting his work, the symptoms reap-
peared and were aggravated. At presentation, a blood differen-
tial count including eosinophils (555 cells/μL), serum biochem-
istry, and chest and paranasal sinus radiographs showed no ab-
normalities. The total IgE was 275 kU/L (normal range 0–114 
kU/L). Skin prick tests were negative for 50 common inhalant 
allergens. NSAH to methacholine was not noted. To evaluate 
the causal relationship, a specific bronchial provocation test 
with hydroxyapatite powder was performed. After inhaling the 
hydroxyapatite powder for 45 min, the forced expiratory volume 
in 1 second (FEV1) decreased to 20% of the baseline value (Fig. 
1). The next day, no NSAH to methacholine was seen (Fig. 2). 
The peripheral blood examination revealed a slightly increased 
eosinophil level to 875 cells/μL after the specific bronchial prov-
ocation test with hydroxyapatite. The patient was diagnosed as 
having hydroxyapatite-induced OA without an increased NSAH 
to methacholine.
DISCUSSION
This is a very unusual case of OA with an early asthmatic reac-
tion to a specific allergen challenge without NSAH before or af-
ter the specific allergen provocation test. The occurrence of an 
asthmatic reaction without NSAH has been described in some 
cases.
3,4 Similar to two reported cases, our subject had negative 
results on methacholine bronchial challenge tests before and 
after the asthmatic reaction. When he visited our department 
for evaluation of his chest symptoms, the patient had already 
been off work for approximately 1 month. This might explain 
the negative NSAH before the specific bronchial provocation 
test. We also performed specific bronchial challenge tests with 
a placebo (wheat flour) to rule out a non-specific irritative reac-
tion. This test was negative, so we were able to exclude the pos-
sibility of a false positive response to hydroxyapatite. However, 
we did not perform a specific bronchial provocation test with 
hydroxyapatite in patients with asthma who had not been ex-
posed to hydroxyapatite. This is a limitation of our study.
Serial measurement of the peak expiratory flow with the sub-
ject at work and away from work would be useful for obtaining 
objective information to confirm OA.
5 However, the patient 
would not agree to peak-expiratory flow rate monitoring. Nev-
ertheless, his chest symptoms were closely related to his work 
hours, and subsided while he was on holiday.
In this study, there was no NSAH to methacholine after the 
specific bronchial provocation test with hydroxyapatite. We used 
the five (total lung capacity)-breath dosimeter method, as mod-
ified from a method described by the American Academy of Al-
lergy and Immunology.
6 In contrast to the modified tidal breath-
ing method of Cockcroft et al.
7, this method may cause bron-
choprotection and give a false-negative result. Recent studies 
performed in large numbers of individuals showed that ap-
proximately equivalent results for the two methods are seen in 
subjects with mild to moderate or greater airway hyperrespon-
sivenss.
8 However, the five-breath dosimeter method might pro-
tect from bronchoconstriction to methacholine in asthmatics 
with very mild airway hyperresponsiveness.
9,10 These findings 
may result in the negative response regarding NSAH to metha-
choline seen in our patient.
The peripheral blood examination showed an increased eo-
sinophil count after the specific bronchial provocation test with 
hydroxyapatite in this case. This suggests that the occurrence of 
NSAH is unlikely to be induced by eosinophilic airway inflam-
mation alone. Eosinophilic bronchitis is one of the important 
diseases characterized by airway inflammation without NSAH.
11 
It is possible that in subjects with very low baseline responsive-
Fig. 1.  Dose-response curves for the specific bronchial provocation tests with 
hydroxyapatite and placebo (rectangles, hydroxyapatite; circles, placebo).
FEV1, forced expiratory volume in 1 second.
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Fig. 2.  Methacholine bronchial challenge tests on days 1 (top, orange rectan-
gles) and 4 (bottom, green circles). On day 1, the baseline FEV1 was 4.31 L and 
the minimum FEV1 after methacholine inhalation was 4.18 L. On day 4, the 
baseline FEV1 was 4.0 L and the minimum FEV1 after methacholine inhalation 
was 3.99 L.
FEV1, forced expiratory volume in 1 second.
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ness, a great deal of inflammation is necessary to induce airway 
responsiveness.
Hydroxyapatite is a naturally occurring mineral form of calci-
um apatite and is chemically similar to the mineral component 
of bone and hard tissues in mammals.
12 As it is insoluble, we 
could not perform skin tests or other studies to evaluate the im-
munological or non-immunological mechanisms. Further stud-
ies are required to evaluate the chemical and immunological 
characteristics of hydroxyapatite.
Although this case has a few limitations regarding the diagno-
sis of OA, we would like to present it as a very rare case of OA 
induced by hydroxyapatite without accompanying NSAH to 
methacholine. Further efforts are required to identify other cas-
es of OA induced by hydroxyapatite and evaluate their patho-
genetic mechanisms.
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